TAM
ALXN

Trust Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Trust Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,992
Closed -$366K – 205
2021
Q2 		$366K Buy
1,992
+225
+13% +$38.6K 0.05% 135
2021
Q1 		$270K Buy
1,767
+314
+22% +$48.6K 0.04% 151
2020
Q4 		$227K Buy
+1,453
New +$187K 0.03% 145
2018
Q3 		– Sell
-470
Closed -$58K – 119
2018
Q2 		$58K Buy
+470
New +$54.9K 0.02% 62

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Trust Asset Management's ALXN Position: Q3 2021 in Review

Trust Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,992 shares — an estimated $366K sold.

Trust Asset Management first reported a position in ALXN in Q2 2018 and held it in 4 quarters. The position peaked at $366K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Trust Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Trust Asset Management sold 1,992 Alexion Pharmaceuticals shares in Q3 2021, an estimated $366K.
  • Trust Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Trust Asset Management's Alexion Pharmaceuticals position peaked at $366K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Trust Asset Management's 13F filing for Q3 2021, filed 29 Oct 2021.